GMRE

Global Medical REIT Inc

Add to Watchlist

Advanced Chart

6.560

-0.01(-0.152%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

6.630

Open

6.600

VWAP

6.59

Vol

37.86K

Mkt Cap

439.39M

Low

6.560

Amount

249.42K

EV/EBITDA(TTM)

23.95

Total Shares

65.59M

1.24B

EV/OCF(TTM)

17.44

P/S(TTM)

3.08

Global Medical REIT Inc. is an internally managed real estate investment trust (REIT). The Company acquires healthcare facilities and leases those facilities to physician groups and regional and national healthcare systems. The Company conducts its business through a wholly owned subsidiary of its operating partnership, Global Medical REIT L.P. It owns 92.6% of the outstanding common operating partnership units (OP Units) of its operating partnership, with an aggregate of 7.4% of the Operating Partnership owned by holders of long-term incentive plan units (LTIP Units) and third-party limited partners who contributed properties or services to the operating partnership in exchange for OP Units. Its portfolio includes medical office buildings (MOBs), inpatient rehab. facility (IRF), surgical hospitals and others. The Company's portfolio is located in various areas, including Texas, Florida, Ohio, Pennsylvania, Illinois, Arizona, and Michigan.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

37.60M

+8.62%

38.25M

+8.79%

38.04M

+11.01%

Estimates Revision

The market is revising Upward the revenue expectations for Global Medical REIT Inc. (GMRE) for FY2025, with the revenue forecasts being adjusted by 0.2% over the past three months. During the same period, the stock price has changed by -4.09%.

Revenue Estimates for FY2025

Revise Upward

+0.2%

In Past 3 Month

Stock Price

Go Down

-4.09%

In Past 3 Month

8 Analyst Rating

31.55% Upside

Wall Street analysts forecast GMRE stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for GMRE is 8.63 USD with a low forecast of 7.50 USD and a high forecast of 11.75 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

3 Buy

5 Hold

0 Sell

Moderate Buy

31.55% Upside

Current: 6.560

Low

7.50

Averages

8.63

High

11.75

31.55% Upside

Current: 6.560

Low

7.50

Averages

8.63

High

11.75

Alliance Global Partners

Gaurav Mehta

Buy

downgrade

2025-05-29

Reason

Alliance Global Partners

Gaurav Mehta

Price Target

2025-05-29

downgrade

Buy

Reason

Alliance Global Partners analyst Gaurav Mehta lowered the firm's price target on Global Medical REIT to $8.50 from $9.50 and keeps a Buy rating on the shares. The company lowered its common dividend by 28.6%, which is the "right step" given the prior dividend was not covered by 2025 and 2026 estimates, the analyst tells investors in a research note. Going forward, the firm believes improved portfolio performance, including an improvement in occupancy, resolving of tenant issues such as Prospect Medical and the closure of the CEO search could be a positive catalyst for the stock.

BMO Capital

Market Perform

downgrade

2025-05-26

Reason

BMO Capital

Price Target

2025-05-26

downgrade

Market Perform

Reason

BMO Capital lowered the firm's price target on Global Medical REIT to $7.50 from $9.50 and keeps a Market Perform rating on the shares. The firm made changes to its models for a number of REITs due to interest rate changes, recent results, and/or discussions with company management.

Baird

Neutral

downgrade

$10 -> $9

2025-05-08

Reason

Baird

Price Target

$10 -> $9

2025-05-08

downgrade

Neutral

Reason

Baird lowered the firm's price target on Global Medical REIT to $9 from $10 and keeps a Neutral rating on the shares. The firm updated its model following Q1 results which were ahead due to NOI and guidance was unchanged.

Alliance Global Partners

Gaurav Mehta

Buy

downgrade

$11

2025-05-08

Reason

Alliance Global Partners

Gaurav Mehta

Price Target

$11

2025-05-08

downgrade

Buy

Reason

Alliance Global Partners analyst Gaurav Mehta lowered the firm's price target on Global Medical REIT to $9.50 from $11 and keeps a Buy rating on the shares. While there was a decline in occupancy in Q1 and management comments indicate that there could be further decline in occupancy in Q2 and Q3, the company noted that there could be improvement by the end of 2025, the analyst tells investors in a research note. The firm believes that an improved portfolio performance could be a positive catalyst for the stock, adding that it views the current valuation as attractive and believes risk/reward is skewed to the upside at current pricing.

Citizens Capital Markets

Aaron Hecht

Hold

Reiterates

n/a

2025-03-12

Reason

Citizens Capital Markets

Aaron Hecht

Price Target

n/a

2025-03-12

Reiterates

Hold

Reason

Berenberg

Kai Klose

Strong Buy

Initiates

$12

2024-10-18

Reason

Berenberg

Kai Klose

Price Target

$12

2024-10-18

Initiates

Strong Buy

Reason

Berenberg analyst Kai Klose initiated coverage of Global Medical REIT with a Buy rating and $11.75 price target. Healthcare real estate investment trusts in the U.S. were heavily affected by COVID-19, as capital markets took a more cautious view on the sector due to concerns about the solvency of operators, the analyst tells investors in a research note. However, with interest rates likely to take a downward trajectory, the share prices of healthcare REITs have already started to stabilize, contends the Berenberg. As a results, it expects the capital markets will view the supportive market fundamentals for Omega Healthcare Investors and Global Medical REIT more positively given the demographic development of the companies.

See All Ratings

Valuation Metrics

The current forward P/E ratio for Global Medical REIT Inc (GMRE.N) is 101.08, compared to its 5-year average forward P/E of 85.18. For a more detailed relative valuation and DCF analysis to assess Global Medical REIT Inc 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

85.18

Current PE

101.08

Overvalued PE

372.79

Undervalued PE

-202.42

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

Undervalued

5Y Average EV/EBITDA

13.97

Current EV/EBITDA

12.09

Overvalued EV/EBITDA

15.67

Undervalued EV/EBITDA

12.28

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Undervalued

5Y Average PS

5.26

Current PS

2.89

Overvalued PS

6.79

Undervalued PS

3.72